LGALS3 and heart failure: Similarly, emerging evidence suggests that novel heart failure therapies like sodium-glucose cotransporter two inhibitors (SGLT2i) and sacubitril/valsartan may contribute to lowering Gal-3 levels, potentially reflecting their beneficial impact on cardiac fibrosis and inflammation.